ALBT

👉  ALBT is TODAY’S #1 ALERT 👈

Yo, have you seen what’s going on with Avalon Globocare (NASDAQ: ALBT)?
This ain’t your average sleepy micro-cap. This is a company in full transformation mode—like a biotech version of Jason Bond doing DMT with a laptop and lab coat.

🧬 First off—innovation city, baby:

Avalon’s been rolling out futuristic tech like the KetoAir™ breathalyzer, which lets you monitor your ketosis with a puff of air. That’s some Tony Stark-level stuff for the keto crowd. But it gets even better…

Avalon’s not just dropping the KetoAir™ and walking away, man. They’re going full beast mode with partnerships that actually move the needle.

First up, they teamed up with Pounds Transformation Clinics—and rolled out this whole “BrAce 4 Impact Challenge Series.” Sounds like a UFC title fight, but it’s a legit program using the KetoAir™ device to help folks shred pounds and dial in their metabolism. We’re talkin’ personalized, data-driven fat loss here—not some cookie-cutter diet plan.

And it gets even cooler—Avalon also partnered with SpecialtyHealth, Inc. to bring KetoAir™ into first responder fitness programs. Yeah. Firefighters, cops, EMTs—these real-life superheroes are now using Avalon tech to monitor their metabolism in real time. It’s like strapping a tiny lab to your belt and getting instant feedback on your performance.

This isn’t some gimmicky fitness toy. It’s biohacking, man. Real science, real partnerships, real impact.

🧬 Second—MIT, baby:

They partnered with MIT scientists to develop their QTY Code Protein Design platform—think of it like a blueprint to rewire how proteins work in the body. Insane potential in diagnostics and therapeutics.

So Avalon Global (ALBT) didn’t just roll out a fancy breathalyzer and call it a day—they teamed up with MIT scientists to build something that honestly sounds like it came out of a Marvel movie.

Let me introduce you to the QTY Code Protein Design Platform.

Now hang with me here—because this is wild. What they’re doing is basically rewriting how proteins behave in the human body. Imagine you’ve got these problematic proteins—let’s say they clump up, don’t dissolve well, don’t respond to treatments. Avalon’s tech takes those bad boys and gives them a full-on genetic jiu-jitsu flip.

With this MIT-collab platform, they’re swapping out parts of those proteins with water-loving amino acids—no genetic modification, no Frankenstein vibes—just elegant science. The result? Proteins that are more stable, more effective, and easier to work with in drugs and diagnostics.

This could literally open the floodgates for next-gen treatments, diagnostics, and synthetic biology breakthroughs.

It’s like CRISPR met a Zen master and started doing hot yoga together. Clean, efficient, powerful.

Avalon didn’t just slap their logo on someone else’s research—they’re co-developing this tech with Dr. Shuguang Zhang, one of the OGs from the MIT Media Lab. This guy’s a pioneer in biomolecular engineering. We’re talking about someone who lives 10 years in the future, easy.

🤖 Now here’s the real kicker—they just inked a deal to merge with YOOV, a Hong Kong-based AI automation beast.

YOOV builds software that automates businesses with zero code. Post-merger, the combined company’s gonna trade under “YOOV” on Nasdaq. That’s a biotech–AI hybrid play. You’re not just betting on Avalon—you’re betting on the rise of machine-enhanced medicine.

Alright, here’s the deal—

• YOOV, this AI automation beast outta Hong Kong, just dropped some serious numbers, man. We’re talkin’ $45.7 million in revenue and $3.4 million in net income for 2024. And get this—it’s unaudited, but still, that’s a straight-up 59% jump from the year before.
• Last year they were at $28.7 million… and even took a $2.4 million loss. But now? Boom—profitable. They flipped the script and came out swinging like a tech heavyweight.

These guys aren’t just growing—they’re scaling like mad. And in the world of AI automation? That kind of momentum is a rocketship waiting to launch.

This ain’t some startup burning cash. YOOV is making money. And they’re merging with Avalon? Dude, this combo could be dangerous.

🔥 And yeah, the float? Practically nonexistent.

This thing’s a powder keg. The tiniest bit of volume and it rips like a monkey on a motorcycle. ALBT has a history of explosive intraday moves. Perfect setup for traders who love catching lightning in a bottle.

📈 December 5 — this thing closes at $2.66, and the very next day it explodes to $6.55. That’s a +146% rocket launch—in 24 freakin’ hours. Straight bottle-rocket vibes.

📈 February 13 — opens at $3.50, and over the next few weeks, it rips all the way to $11.66 by March 4. That’s a +233% move, dude. Not even joking. That’s the kind of move that turns day traders into legends.

📈 And just recently? It closed at $4.81 March 18 — then ripped to $7.89 in just a few days. That’s another +64% sprint, like it caught a second wind and took off.

This stock isn’t just moving—it’s swinging like a chimp on pre-workout. You get the timing right on ALBT, and it’s like catching lightning in a Red Bull can.

Keep this thing on your radar, man. It’s got that “spikeability”—you know the kind. Low float, momentum-friendly, and it doesn’t need a whole lotta volume to go vertical.

🧠 Final thoughts:

So yeah…
You’ve got AI automation with YOOV,
you’ve got medical devices with KetoAir,
and now you’ve got protein engineering tech straight from MIT.

This isn’t just a stock—it’s a damn sci-fi startup that somehow landed on the Nasdaq under everyone’s radar.

Bro… if this QTY platform even half delivers, we’re looking at something that could seriously shake up the entire biotech scene.

Wild times. Keep your third eye open on this one. 🧬💥

If you like high-growth sectors, bleeding-edge tech, and you’re not afraid of some risk, ALBT is the kind of moonshot play that could go from “what is this?” to “holy s*, why didn’t I look at it back then?”

Just don’t sleep on this merger—it could be the fuse that lights the rocket.

Keep your eyes on the chart. Set your alerts. Avalon (ALBT) might just be the most interesting stock at the biotech-AI intersection right now. 💥🧬🤖

You want in before the rest of the market wakes up.

Hey, have a look for yourself. Pull up ALBT on your trading platform this morning.

Eat. Sleep. TRADE!

Jason Bond

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, Sherwood Ventures has received twenty five thousand dollars (cash) from Shore Thing Media, and Jason Bond LLC has been paid five thousand of that amount for a one day marketing program starting on April 16, 2025. These amounts were paid by someone else not connected to Avalon Globocare. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Jason Bond LLC nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Avalon Globocare might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Jason Bond LLC nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.